Evidence map›Paper›PMID 35597847›Full record

ArticleAnnals of hematology2022

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.

Jil Rotterdam, Margot Thiaucourt, Christel Weiss, Juliana Schwaab, Andreas Reiter, Sebastian Kreil, Laurenz Steiner, Sebastian Fenchel, Henning D Popp, Wolf-Karsten Hofmann and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Jil RotterdamDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Margot ThiaucourtInstitute for Clinical Chemistry, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Christel WeissDepartment of Medical Statistics, Biomathematics and Information Processing, Center for Preventive Medicine and Digital Health Baden-Württemberg (CPD-BW), University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Juliana SchwaabDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Andreas ReiterDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Sebastian KreilDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Laurenz SteinerDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Sebastian FenchelDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Henning D PoppDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Karin BonatzDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Catharina GerhardsInstitute for Clinical Chemistry, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Michael NeumaierInstitute for Clinical Chemistry, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Stefan A KleinDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Sonika RaoInstitute for Clinical Chemistry, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Mohamad JawharDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Susanne SausseleDepartment of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. Susanne.Saussele@medma.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-0357-5785
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors is limited. In this single-center study, antibody levels of the SARS-CoV-2 spike protein were measured ≥ 2 weeks after 2nd COVID-19 vaccination with a concentration ≥ 0.8 U/mL considered positive. Between July and October 2021, in a total of 373 patients (median age 64 years, 44% women) with myeloid neoplasms (n = 214, 57%), lymphoid neoplasms (n = 124, n = 33%), and other diseases (n = 35, 10%), vaccination was performed with BNT162b2 (BioNTech), mRNA-1273 (Moderna), ChADOx1 (AstraZeneca), or a combination. A total of 229 patients (61%) were on active therapy within 3 months prior vaccination and 144 patients (39%) were previously treated or treatment naïve. Vaccination-related antibody response was negative in 56/373 patients (15%): in 39/124 patients with lymphoid neoplasms, 13/214 with myeloid neoplasms, and 4/35 with other diseases. Active treatment per se was not correlated with negative response. However, rituximab and BTK inhibitor treatment were correlated significantly with a negative vaccination response, whereas younger age and chronic myeloid leukemia (CML) disease were associated with positive response. In addition, 5 of 6 patients with myeloproliferative neoplasm (MPN) and negative vaccination response were on active treatment with ruxolitinib. In conclusion, a remarkable percentage of patients with hematological diseases had no response after 2nd COVID-19 vaccination. Multivariable analysis revealed important factors associated with response to vaccination. The results may serve as a guide for better protection and surveillance in this vulnerable patient cohort.

Indexed as

Antibody FormationCOVID-19COVID-19 VaccinesHematologic DiseasesAntibodies, ViralBNT162 VaccineFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedMyeloproliferative DisordersSARS-CoV-2Spike Glycoprotein, CoronavirusTreatment FailureVaccinationAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19 vaccinationHematological diseases/disordersSARS-CoV-2Seroconversion

Identifiers

PMID35597847
PMCPMC9124009
OpenAlexW4281258659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.